Parenteral form of ibuprofen for pain relief in the early postoperative period in cancer patients after thoracoscopic and bone-plastic surgery

Aim. То compare the safety of use and the analgesic effect of postoperative anesthesia regimens using non-steroidal anti-inflammatory drug (NSAID) – Intrafen-GEN (ibuprofen) with a scheme of postoperative anesthesia based on narcotic analgesics in oncological patients after thoracoscopic and bone-plastic surgery. To evaluate the possibilities of using a postoperative anesthesia regimen using NSAIDs – Intrafen-GEN (ibuprofen) within the framework of the ERAS protocol (Enhanced Recovery After Surgery).

Materials and methods. A single-center prospective comparative study conducted at the N.N. Trapeznikov Research Institute of Clinical Oncology in 2024–2025 included 98 patients who underwent minimally invasive thoracic and bone-plastic surgery.

Results. Based on the area of surgical intervention, all patients (n=98) were divided first into 2 groups, and then into subgroups A and B, according to the schemes of postoperative anesthesia. The first group included 64 patients. It was divided into subgroups A (n = 34) and B (n = 30). The second group included 34 patients and was also divided into subgroups A and B with an equal number of patients in each of the subgroups (n = 17). Patients in subgroup A received a postoperative pain relief regimen using Intrafen-GEN (ibuprofen), and patients in subgroup B received a regimen using trimeperidine. The first intravenous dose of Intrafen-GEN (ibuprofen) – 800 mg was administered 30 minutes before the end of surgery or immediately upon admission to the intensive care unit, then every 8–12 hours for 3 days. In the case of persistent pain, non-opioid and opioid analgesics were added to the treatment until the pain completely disappeared. Patients in subgroup B received anesthesia with trimeperidine 20 mg intramuscularly every 8 hours for 3 postoperative days. The quality of anesthesia in the postoperative period was assessed using the visual analog scale.

Conclusion. In our study, Intrafen-GEN (ibuprofen) was found to be a safe drug, as no complications or side effects were observed during its use. The pain management regimens based on Intrafen-GEN (ibuprofen) demonstrated the complete elimination of opioid analgesics from postoperative pain management in 24 (70.59 %) patients after thoracoscopic surgeries and in 10 (58.85 %) patients after bone-plastic surgeries. When using Intrafen-GEN (ibuprofen), there are no contraindications for the ERAS protocol and early activation of patients in the ICU.